PCSK9 and metabolic syndrome: The currently used drugs for dyslipidemia include HMG-CoA reductase inhibitors, anion exchange resins, CHO transporter inhibitors that inhibit CHO absorption from the small intestine, fibrates that enhance lipid metabolism, polyunsaturated fatty acids such as DHA/EPA, and proprotein convertase subtilisin/kexin type 9 inhibitors [37].